A Phase II study of ONO-4538 in patients with relapsed or metastatic malignant melanoma
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 01 Nov 2018 Results evaluating risk factors and the clinical course of Thyroid Disfunction induced by nivolumab ONO-4538-01, ONO-4538-02, ONO-4538-04, ONO-4538-05, ONO-4538-06, and ONO-4538-08, published in the Cancer Science.
- 19 Oct 2018 Results of a pooled population pharmacokinetics and exposure-safety analysis from 9 studies, published in the Journal of Clinical Pharmacology.
- 25 Nov 2016 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History